In a randomized controlled trial by Arnold et al. [15] involving 109 participants with metastatic midgut or pancreatic NETs, patients were randomized to receive either thrice-daily octreotide (study preceded the development of long-acting SSAs) and thrice-weekly IFN-a or octreotide monotherapy. The gene discussed is IFNA1; the disease is pancreatic neuroendocrine tumor.